External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ESMO Breast Cancer 2025
Roche and Genentech at

ESMO Breast Cancer 2025

May 14 - May 17
Munich, Germany / Virtual (Hybrid)
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
10:00 AM
Duration 45mins Munich, Germany
INAVO123: Phase III study of first-line (1L) inavolisib/placebo + a CDK4/6 inhibitor + letrozole (INAVO/PBO + CDK4/6i + LET) in participants (pts) with PIK3CA-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-sensitive advanced breast cancer (aBC)
J. Cortes, R. Basho, K. Jhaveri, J. King, S. Kummel, V. Krishnan, P. Gyamfi, LX Liu, V. Khor, A. Mani, YH Park
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:45 AM
Duration 45mins Munich, Germany
Anaphylaxis/hypersensitivity with the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC)in HER2-positive breast cancer (HER2+ BC)
SM. Tolaney, E. Hamilton, C. Palmieri, Y. Ozaki, M. Shivhare, S. Heeson, E. Restuccia, TK Janićijević, V. Revelant, S. Kümmel
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 45mins Munich, Germany
Utilizing Natural Language Processing to examine Adverse Events in HER2+ Breast Cancer Patients
S. Chumsri, CC. O'Sullivan, H. Goldberg, S. Venkateswaran, E. Silvert, T. Wagner, R. Poppe, M. Genevray, R. Mohindra, T. Sanglier
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:13 PM
Duration 12mins Munich
Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years’ median follow-up
Sibylle Loibl
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.